AU2010333574B2 - Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof - Google Patents

Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof Download PDF

Info

Publication number
AU2010333574B2
AU2010333574B2 AU2010333574A AU2010333574A AU2010333574B2 AU 2010333574 B2 AU2010333574 B2 AU 2010333574B2 AU 2010333574 A AU2010333574 A AU 2010333574A AU 2010333574 A AU2010333574 A AU 2010333574A AU 2010333574 B2 AU2010333574 B2 AU 2010333574B2
Authority
AU
Australia
Prior art keywords
atom
leu
ala
cancer
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010333574A
Other languages
English (en)
Other versions
AU2010333574A1 (en
Inventor
Dacheng Wang
Guangwen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Superlab Far East Ltd
Original Assignee
Superlab Far East Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Superlab Far East Ltd filed Critical Superlab Far East Ltd
Publication of AU2010333574A1 publication Critical patent/AU2010333574A1/en
Assigned to SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP. reassignment SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP. Amend patent request/document other than specification (104) Assignors: SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.
Assigned to SUPERLAB FAR EAST LIMITED reassignment SUPERLAB FAR EAST LIMITED Request for Assignment Assignors: SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.
Application granted granted Critical
Publication of AU2010333574B2 publication Critical patent/AU2010333574B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Computing Systems (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2010333574A 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof Active AU2010333574B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910259339.2 2009-12-18
CN2009102593392A CN102101886A (zh) 2009-12-18 2009-12-18 构象改变的重组干扰素晶体、其三维结构及应用
PCT/CN2010/002055 WO2011072487A1 (zh) 2009-12-18 2010-12-16 空间构象改变的重组干扰素的晶体、其三维结构及应用

Publications (2)

Publication Number Publication Date
AU2010333574A1 AU2010333574A1 (en) 2012-07-19
AU2010333574B2 true AU2010333574B2 (en) 2017-03-09

Family

ID=44154975

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010333574A Active AU2010333574B2 (en) 2009-12-18 2010-12-16 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof

Country Status (11)

Country Link
US (3) US8846025B2 (enExample)
EP (1) EP2514761B1 (enExample)
JP (2) JP2013514279A (enExample)
KR (1) KR20120108985A (enExample)
CN (2) CN102101886A (enExample)
AU (1) AU2010333574B2 (enExample)
CA (1) CA2784624C (enExample)
ES (1) ES2631028T3 (enExample)
MY (1) MY169650A (enExample)
SG (1) SG181785A1 (enExample)
WO (1) WO2011072487A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9830422B1 (en) * 2013-07-22 2017-11-28 The Curators Of The University Of Missouri In silico biological and pharmaceutical modeling
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
EP3294321B1 (en) * 2015-05-12 2024-07-31 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
US11562806B2 (en) * 2018-05-09 2023-01-24 Shenzhen Jingtai Technology Co., Ltd. Drug crystal structure landscape analysis system and landscape analysis method thereof
CN111508568B (zh) * 2020-04-20 2023-08-29 腾讯科技（深圳）有限公司 分子生成方法、装置及计算机可读存储介质和终端设备
CN111658779A (zh) * 2020-06-22 2020-09-15 四川大学华西医院 治疗新型冠状病毒肺炎的联合用药物
CN113223631B (zh) * 2021-05-06 2024-05-24 吉林大学 一种晶体结构解析方法及系统
CN119670712B (zh) * 2024-11-28 2025-10-03 中国人民解放军总医院 基于bert模型的临床知情同意书智能推荐装置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311035A (zh) * 2001-02-28 2001-09-05 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
WO2002086156A2 (en) * 2001-04-24 2002-10-31 Genodyssee New polynucleotides and polypeptides of the ifn$g(a)-17 gene
CN1740197A (zh) * 2004-08-26 2006-03-01 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
AU2887099A (en) 1998-03-06 1999-09-20 Abbott Laboratories Ligand screening and design by x-ray crystallography
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
IL155741A0 (en) 2000-11-03 2003-12-23 Pbl Biomedical Lab Interferons, uses and compositions related thereto
US20060035327A1 (en) 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
CN101001644B (zh) * 2003-08-28 2011-09-21 辉阳科技美国公司 空间构象改变的干扰素及其应用
KR20060130009A (ko) * 2003-08-28 2006-12-18 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
ES2528218T3 (es) 2003-08-28 2015-02-05 Superlab Far East Limited Usos de interferones con estructura espacial modificada
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
JP2006083126A (ja) * 2004-09-17 2006-03-30 Institute Of Physical & Chemical Research タンパク質の結晶化試薬キット及び試薬キットを利用した結晶化スクリーニング方法
EP1868636A4 (en) * 2005-03-09 2012-03-28 Guangwen Wei USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS
CN1710197B (zh) * 2005-06-17 2011-06-22 徐州师范大学 可变色彩色纤维防伪纸
JP4744979B2 (ja) * 2005-08-24 2011-08-10 独立行政法人理化学研究所 ゼオライトを用いたタンパク質結晶化方法
JP2008050225A (ja) * 2006-08-25 2008-03-06 National Institute Of Advanced Industrial & Technology たんぱく質の合理的な結晶化条件探索法
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
US20130184437A9 (en) 2011-06-08 2013-07-18 Guangwen Wei Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
CN1311035A (zh) * 2001-02-28 2001-09-05 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US7364724B2 (en) * 2001-02-28 2008-04-29 Sichuan Biotechnology Research Center Recombinant super-compound interferon
WO2002086156A2 (en) * 2001-04-24 2002-10-31 Genodyssee New polynucleotides and polypeptides of the ifn$g(a)-17 gene
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CN1740197A (zh) * 2004-08-26 2006-03-01 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用

Also Published As

Publication number Publication date
EP2514761A9 (en) 2013-02-06
US20120308520A1 (en) 2012-12-06
CA2784624C (en) 2021-05-04
AU2010333574A1 (en) 2012-07-19
JP2016128507A (ja) 2016-07-14
SG181785A1 (en) 2012-07-30
CN102101886A (zh) 2011-06-22
US20140356324A1 (en) 2014-12-04
EP2514761A1 (en) 2012-10-24
WO2011072487A1 (zh) 2011-06-23
US8415151B2 (en) 2013-04-09
HK1177749A1 (en) 2013-08-30
MY169650A (en) 2019-04-25
ES2631028T3 (es) 2017-08-25
JP2013514279A (ja) 2013-04-25
EP2514761A4 (en) 2013-08-28
EP2514761B1 (en) 2016-11-23
US8846025B2 (en) 2014-09-30
CN102770447A (zh) 2012-11-07
CN102770447B (zh) 2015-03-11
KR20120108985A (ko) 2012-10-05
US20110158941A1 (en) 2011-06-30
CA2784624A1 (en) 2011-06-23
US9273109B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
AU2010333574B2 (en) Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
Arold et al. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling
US8114395B2 (en) Treatment of viral diseases with recombinant interferon α
Khan et al. A protein coupling and molecular simulation analysis of the clinical mutants of androgen receptor revealed a higher binding for Leupaxin, to increase the prostate cancer invasion and motility
US8287852B2 (en) Treatment of viral diseases with recombinant interferon α
Joshi et al. Elucidating the molecular interactions of chemokine CCL2 orthologs with flavonoid baicalin
US20150031859A1 (en) Use of new recombinant interferons with altered spatial configuration and three-dimensional structure
KR20030074788A (ko) 감소된 면역원성을 갖는 개질 렙틴
Yedidi et al. Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants
US20090220456A1 (en) Uses of interferons with altered spatial structure
WO2005034853A2 (en) Uses of interferons with altered spatial structure
Li et al. Virtual screening of potato virus Y coat protein for discovering lead inhibitors of viral intercellular traffic
TWI513706B (zh) The spatial conformation changes the reconstructed interferon crystal, its three - dimensional structure and its application
KR20050010898A (ko) 감소된 면역원성을 갖는 개질 브리오딘 1
Radha et al. In Silico approach to inhibit Synthetic HIV-TAT activity using Phytoconstituents of Moringa oleifera leaves extract
Shahid et al. In-silico Evaluation of Novel Honokiol Derivatives against Breast Cancer Target Protein LKB1
Ray et al. Mutational analysis of interleukin-11 and its consequences on cancer and COVID-19 related cytokine storm-an extensive molecular dynamics study
You et al. Model for the yeast cofactor A–β-tubulin complex based on computational docking and mutagensis
JP2008520734A (ja) Ｐｆ４ファーマコフォア及びそれらの使用
Barla et al. IN SILICO EVALUATION OF TRYPSIN INHIBITOR WITH ANTIPROLIFERATIVE AND ANTIFUNGAL PROPERTIES FROM TESTA OF C. LANATUS
Rokan et al. GLOBAL ACADEMIC RESEARCH INSTITUTE
Skariyachan et al. In silico investigation and docking studies of E2F3 tumour marker: discovery and evaluation of potential inhibitors for prostate and breast cancer
Al-Mulla et al. SURVIVIN TARGETING; AN IN SILICO APPROACH FOR ANTICANCER DESIGN
WO2012141794A2 (en) Crystal structure and peptide inhibitors of hausp deubiquitinase

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUPERLAB FAR EAST LIMITED

Free format text: FORMER APPLICANT(S): SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.

FGA Letters patent sealed or granted (standard patent)